A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

Last updated: January 13, 2026
Sponsor: Neurocentria, Inc.
Overall Status: Terminated

Phase

2

Condition

Attention Deficit/hyperactivity Disorder (Adhd - Adults)

Williams Syndrome

Treatment

NRCT-101SR, NRCT-202XR

Clinical Study ID

NCT06673368
NC-022A
  • Ages 13-17
  • All Genders

Study Summary

A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.

Eligibility Criteria

Inclusion

  1. Male or female, 13-17 years of age at screening.

  2. Has a prior primary diagnosis of ADHD according to the DSM-5 classification evident by a medical record and confirmed with MINI using DSM-5 probes.

  3. Is taking ADHD medication 4-7 days/week, for at least 4 weeks at Screening and at least 6 weeks at Baseline.

  4. Has side effects identified using SDSE-RS at Screening and Baseline.

  5. CGI-S ≥ X (blinded) at Screening and Baseline.

  6. Must be fluent in English and communicate effectively with others.

  7. Both subject and parent/guardian willing and able to give informed assent/consent.

  8. Parent/guardian willing to serve as informant.

Study Design

Total Participants: 2
Treatment Group(s): 1
Primary Treatment: NRCT-101SR, NRCT-202XR
Phase: 2
Study Start date:
February 25, 2025
Estimated Completion Date:
July 15, 2025

Study Description

A multi-center, randomized, double-blind, parallel, adaptive-design clinical trial to evaluate the safety and efficacy of co-administration of NRCT-101SR and low dose NRCT- 202XR compared to low or high dose of NRCT-202XR and placebo NRCT-101SR over a 6-week period in approximately 60 pediatric subjects (13-17 years of age) with ADHD.

Subjects' enrollment will be conducted in two stages.

In stage 1, subjects are planned to be randomized to one of the following two arms (1:1 ratio):

Arm 1: NRCT-101SR and low dose NRCT-202XR Arm 2: NRCT-101SR placebo and high dose NRCT-202XR

In stage 2, a third study arm will be added (Arm 3 - NRCT-101SR placebo and low dose NRCT-202XR.

The study population will include male and female subjects (sex assigned at birth) of all races/ethnicities with ADHD.

Connect with a study center

  • Accel Research Site-Maitland Clinical Research Unit

    Maitland, Florida 32751
    United States

    Site Not Available

  • Accel Research Site-Maitland Clinical Research Unit

    Maitland 4163220, Florida 4155751 32751
    United States

    Site Not Available

  • iResearch Atlanta

    Decatur, Georgia 30030
    United States

    Site Not Available

  • iRresearch Atlanta

    Decatur, Georgia 30030
    United States

    Active - Recruiting

  • CenExel iRS - iResearch Savannah

    Savannah, Georgia 31405
    United States

    Site Not Available

  • iResearch Atlanta

    Decatur 4191124, Georgia 4197000 30030
    United States

    Site Not Available

  • CenExel iRS - iResearch Savannah

    Savannah 4221552, Georgia 4197000 31405
    United States

    Site Not Available

  • Boston Clinical Trials LLC

    Boston, Massachusetts 02131
    United States

    Site Not Available

  • Boston Clinical Trials LLC

    Boston 4930956, Massachusetts 6254926 02131
    United States

    Site Not Available

  • Center For Psychiatry and Behavioral Medicine

    Las Vegas, Nevada 89128
    United States

    Site Not Available

  • Center For Psychiatry and Behavioral Medicine

    Las Vegas 5506956, Nevada 5509151 89128
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.